The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TNGX | +703.32% | +52.43% | +8.79% | +66% |
| S&P | +17.45% | +75.43% | +11.88% | +95% |
Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.
This clinical-stage biotech develops targeted cancer therapies, leveraging strategic partnerships and a differentiated oncology pipeline.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | -100.0% |
| Gross Profit | -$479.00K | -113.7% |
| Gross Margin | 98.97% | 4.3% |
| Market Cap | $1.19B | 259.5% |
| Market Cap / Employee | $8.71M | 0.0% |
| Employees | 137 | -11.6% |
| Net Income | -$38,749.00K | -2.9% |
| EBITDA | -$41,385.00K | -2.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $112.71M | 62.1% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $30.83M | -9.4% |
| Short Term Debt | $2.74M | 11.6% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -27.50% | 7.5% |
| Return On Invested Capital | -51.88% | -1.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$29,940.00K | 18.6% |
| Operating Free Cash Flow | -$29,718.00K | 18.9% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.74 | 3.32 | 6.90 | 6.18 | 326.49% |
| Price to Sales | 3.69 | 23.29 | 14.02 | 18.69 | 134.12% |
| Price to Tangible Book Value | 0.74 | 3.32 | 6.90 | 6.18 | 326.49% |
| Enterprise Value to EBITDA | 0.69 | -10.41 | 55.63 | -20.68 | 628.31% |
| Return on Equity | -61.3% | -76.1% | -51.7% | -37.2% | -35.33% |
| Total Debt | $36.95M | $35.01M | $34.76M | $33.57M | -8.01% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
